ID   NCC-IT
AC   CVCL_1451
SY   NCCIT
DR   BTO; BTO:0004180
DR   CLO; CLO_0007955
DR   ArrayExpress; E-MTAB-783
DR   ATCC; CRL-2073
DR   BCRC; 60314
DR   BCRJ; 0369
DR   BioSample; SAMN03471433
DR   cancercelllines; CVCL_1451
DR   CCRID; 3101HUMTCHu238
DR   Cell_Model_Passport; SIDM00655
DR   ChEMBL-Cells; CHEMBL3308379
DR   ChEMBL-Targets; CHEMBL1075511
DR   CLS; 305080
DR   Cosmic; 687051
DR   Cosmic; 908441
DR   Cosmic; 1090412
DR   Cosmic; 2077186
DR   Cosmic; 2163758
DR   Cosmic; 2807074
DR   Cosmic-CLP; 908441
DR   DepMap; ACH-001578
DR   GEO; GSM1670159
DR   IARC_TP53; 21532
DR   NCBI_Iran; C624
DR   PharmacoDB; NCCIT_999_2019
DR   PRIDE; PXD030251
DR   PRIDE; PXD030304
DR   PubChem_Cell_line; CVCL_1451
DR   Wikidata; Q17578676
RX   PubMed=2842544;
RX   PubMed=9331070;
RX   PubMed=20164919;
RX   PubMed=24812411;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=31500094;
RX   PubMed=35084545;
RX   PubMed=35839778;
WW   https://de.wikipedia.org/wiki/NCC-IT
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 6844; MAP2K4; Simple; p.Lys309Asn (c.927G>C); Zygosity=Unspecified (PubMed=9331070).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg173Pro (c.518G>C); ClinVar=VCV000185195; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val272Cysfs*73 (c.814delG); Zygosity=Homozygous (Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=81.79%; East Asian, South=18.2%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Misspelling: NCC15; Cosmic=2163758; PubMed=24812411.
ST   Source(s): ATCC; DepMap; Cosmic-CLP
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 11
ST   D16S539: 9,12
ST   D18S51: 13,14
ST   D21S11: 29,32.2
ST   D3S1358: 16
ST   D5S818: 10,13
ST   D7S820: 10
ST   D8S1179: 10,15
ST   FGA: 22,26
ST   Penta D: 10,12
ST   Penta E: 5,14
ST   TH01: 7,9
ST   TPOX: 8
ST   vWA: 14,18
DI   NCIt; C6341; Testicular embryonal carcinoma
DI   ORDO; Orphanet_289362; Non-central nervous system-localized embryonal carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   24Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 38
//
RX   PubMed=2842544;
RA   Teshima S.-i., Shimosato Y., Hirohashi S., Tome Y., Hayashi I.,
RA   Kanazawa H., Kakizoe T.;
RT   "Four new human germ cell tumor cell lines.";
RL   Lab. Invest. 59:328-336(1988).
//
RX   PubMed=9331070;
RA   Teng D.H.-F., Perry W.L. III, Hogan J.K., Baumgard M.L., Bell R.,
RA   Berry S., Davis T., Frank D., Frye C., Hattier T., Hu R.,
RA   Jammulapati S., Janecki T., Leavitt A., Mitchell J.T., Pero R.,
RA   Sexton D., Schroeder M., Su P.-H., Swedlund B., Kyriakis J.M.,
RA   Avruch J., Bartel P., Wong A.K.C., Oliphant A., Thomas A.,
RA   Skolnick M.H., Tavtigian S.V.;
RT   "Human mitogen-activated protein kinase kinase 4 as a candidate tumor
RT   suppressor.";
RL   Cancer Res. 57:4177-4182(1997).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=24812411; DOI=10.1158/1078-0432.CCR-13-2868;
RA   Feldman D.R., Iyer G., Van Alstine L., Patil S., Al-Ahmadie H.,
RA   Reuter V.E., Bosl G.J., Chaganti R.S.K., Solit D.B.;
RT   "Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but
RT   not BRAF in cisplatin-resistant germ cell tumors.";
RL   Clin. Cancer Res. 20:3712-3720(2014).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31500094; DOI=10.3390/cancers11091316;
RA   Bakardjieva-Mihaylova V., Skvarova Kramarzova K., Slamova M.,
RA   Svaton M., Rejlova K., Zaliova M., Dobiasova A., Fiser K., Stuchly J.,
RA   Grega M., Rosova B., Zachoval R., Klezl P., Eis V., Kindlova E.,
RA   Buchler T., Trka J., Boublikova L.;
RT   "Molecular basis of cisplatin resistance in testicular germ cell
RT   tumors.";
RL   Cancers (Basel) 11:1316.1-1316.18(2019).
//
RX   PubMed=35084545; DOI=10.1007/s00345-022-03936-1;
RA   Fichtner A., Bohnenberger H., Elakad O., Richter A., Lenz C., Oing C.,
RA   Strobel P., Kueffer S., Nettersheim D., Bremmer F.;
RT   "Proteomic profiling of cisplatin-resistant and cisplatin-sensitive
RT   germ cell tumour cell lines using quantitative mass spectrometry.";
RL   World J. Urol. 40:373-383(2022).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//